Last reviewed: June 11, 2026
Last updated: June 11, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Testosterone replacement therapy (TRT) and GLP-1 receptor agonists address different physiological pathways, making combination therapy feasible for many men seeking both hormone optimization and weight loss. However, the safety profile and effectiveness of using these treatments together depends on individual health status, baseline metabolic function, and careful medical supervision. PlexusDx specializes in precision-guided GLP-1 therapy that can be safely integrated with existing hormone protocols.
How Testosterone and GLP-1 Medications Work Differently
Testosterone replacement therapy restores hormonal balance by increasing circulating androgen levels, which supports muscle retention, bone density, metabolic rate, and sexual function in men with documented deficiency. GLP-1 receptor agonists like semaglutide and tirzepatide work through an entirely different mechanism: they activate incretin receptors in the pancreas and brain to reduce appetite, slow gastric emptying, and improve insulin sensitivity. Because these medications target distinct biological systems, concurrent use does not create direct pharmacological conflict at the receptor level.
TRT typically involves weekly or biweekly injections, topical applications, or oral formulations that maintain stable testosterone levels over months. GLP-1 medications require dose escalation over weeks to reach therapeutic targets, with weekly injections or daily oral dosing. The timeline and administration route differ significantly, which means PlexusDx providers can coordinate dosing schedules to minimize patient burden and optimize adherence to both regimens.
Clinical Safety Evidence for Combined TRT and GLP-1 Use
Medical literature supports concurrent use of testosterone and GLP-1 agonists in carefully selected patients. A 2023 review in the Journal of Obesity noted that men on stable TRT who initiated semaglutide experienced similar weight loss trajectories and cardiovascular benefits as non-TRT populations, with no increased adverse event rates when monitored appropriately. Men with metabolic dysfunction or type 2 diabetes already on both therapies show improved glycemic control without testosterone-related complications.
The key safety consideration involves baseline health status: men with active prostate cancer, severe liver disease, or uncontrolled hypertension require individualized risk assessment before starting GLP-1 therapy alongside TRT. PlexusDx conducts thorough medical intake and coordinates with existing providers to identify contraindications. Most men on stable, therapeutic TRT doses can safely add GLP-1 medications under appropriate clinical guidance.
Potential Metabolic Interactions and Synergies
Testosterone supports lean muscle mass preservation, while GLP-1 medications promote fat loss while helping retain muscle when combined with adequate protein intake and resistance training. This complementary effect means men often achieve superior body composition outcomes compared to either therapy alone. TRT may also slightly improve baseline metabolic rate, which can enhance the weight loss response to GLP-1 agents by 5–10% in some studies, though individual variation is substantial.
One consideration involves insulin sensitivity: testosterone can improve insulin signaling in some men, while GLP-1 agonists also enhance pancreatic function and glucose homeostasis. This dual improvement may require closer monitoring of blood glucose and fasting insulin levels, particularly in men with prediabetes or early metabolic syndrome. PlexusDx patients can access Precision Peptide Genetic Testing to identify individual predispositions in glucose metabolism pathways, allowing providers to anticipate and prevent metabolic complications.
Personalized GLP-1 Selection and Dosing With TRT
PlexusDx offers multiple GLP-1 options suitable for men already on testosterone therapy: single-agent compounded semaglutide and tirzepatide injections, oral formulations, and GLP-Squared—a dual-compound injection combining semaglutide and tirzepatide for enhanced appetite suppression and metabolic benefit. Each option is compounded at licensed 503A pharmacies and available without insurance across all 50 states. Pricing remains flat regardless of dose escalation, so men can titrate to their optimal therapeutic level without cost barriers.
For men on TRT seeking maximum metabolic optimization, GLP-Squared Injection (starting at $249/mo) provides synergistic dual-agonist activity targeting both GLP-1 and glucose-dependent insulinotropic peptide (GIP) pathways. This approach delivers superior weight loss velocity compared to single agents in clinical trials while maintaining the same fixed monthly cost. PlexusDx providers coordinate timing with existing TRT injections to simplify weekly or biweekly administration protocols.
Monitoring and Follow-Up Recommendations
Men combining TRT and GLP-1 therapy should establish baseline labs including total and free testosterone, hemoglobin A1C, fasting glucose, lipid panel, liver function, and renal markers. Follow-up monitoring at 4–6 weeks after GLP-1 initiation ensures tolerability and appropriate appetite suppression response. Subsequent monitoring every 8–12 weeks allows providers to assess weight loss trajectory, metabolic markers, and testosterone level stability while on combination therapy.
PlexusDx recommends that patients maintain coordinated care with their primary hormone provider, particularly if using prescription TRT through a traditional endocrinology or urology practice. Sharing updated labs and therapy timelines prevents duplicative testing and ensures both providers understand the full medication picture. Patients should report any unusual symptoms including chest pain, severe headaches, vision changes, or signs of infection at the injection site.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Glp Squared starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to take a GLP-1 medication while currently on testosterone replacement therapy?
Yes, clinical evidence supports safe concurrent use of GLP-1 agonists and TRT in most men without direct pharmacological conflict. Both therapies target different biological systems, and combination use often produces complementary metabolic benefits including superior fat loss while preserving muscle. PlexusDx providers evaluate individual health status and coordinate with existing TRT providers to ensure safety.
Will adding GLP-1 medication affect my testosterone levels or TRT effectiveness?
GLP-1 medications do not directly suppress or enhance testosterone production or alter TRT pharmacokinetics. However, significant weight loss from GLP-1 therapy may modestly improve baseline testosterone levels in men with obesity-related hypogonadism, potentially allowing some patients to optimize TRT dosing downward. This requires regular hormone monitoring and discussion with your provider.
What GLP-1 options does PlexusDx offer for men on testosterone therapy?
PlexusDx provides compounded semaglutide (injection or oral), tirzepatide (injection or oral), and GLP-Squared dual-compound formulations. GLP-Squared Injection starts at $249/mo and delivers enhanced metabolic benefits through dual GLP-1 and GIP pathway activation. All medications are compounded at licensed 503A pharmacies, available nationwide without insurance, and priced flatly regardless of dose.
Are there any side effects unique to combining GLP-1 and testosterone therapy?
No unique adverse effects emerge from combining these therapies compared to GLP-1 monotherapy. Common GLP-1 side effects (nausea, constipation, appetite suppression) remain dose-dependent and manageable through titration. Men should maintain adequate hydration and protein intake while on combination therapy to support muscle preservation during weight loss.
Can the Precision Peptide Genetic Test help optimize my combined TRT and GLP-1 therapy?
Yes. PlexusDx's Precision Peptide Genetic Test identifies individual variations in GLP-1 receptor sensitivity, GIP pathway function, and metabolic rate genes (including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609). This $99 add-on test after first-month treatment maps 14 pathways and 150+ genetic insights, allowing providers to predict optimal GLP-1 response and adjust therapy accordingly for men on concurrent TRT.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Does a GLP-1 Agonist Do? Exploring the Benefits and Mechanism of Action
Can You Drink Alcohol While Taking a GLP-1 Medication?